BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2026)

BridgeBio Pharma has reported Current Deferred Revenue for 6 years, with the latest figure at $6.1 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 47.38% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 47.38% YoY) and the FY2025 annual result came in at $7.2 million, up 1697.5% from the prior year.
• Current Deferred Revenue slipped to $6.1 million in Q1 2026 per BBIO's latest filing, from $7.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $100.0 million in Q2 2024 and troughed at $400000.0 in Q4 2024.
• A 5-year average of $19.6 million and a median of $8.3 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue tumbled 93.44% in 2024, then soared 1697.5% in 2025.
• Over 5 years, Current Deferred Revenue stood at $19.8 million in 2022, then tumbled by 69.21% to $6.1 million in 2023, then sank by 93.44% to $400000.0 in 2024, then jumped by 1697.5% to $7.2 million in 2025, then declined by 14.95% to $6.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.1 million, $7.2 million, and $9.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.